Real-world cost-effectiveness of rivaroxaban and apixaban vs VKA in stroke prevention in non-valvular atrial fibrillation in the UK

• Glavni autori: Kevin Bowrin (Autor), Jean-Baptiste Briere (Autor), Pierre Levy (Autor), Aurélie Millier (Autor), Jean Tardu (Autor), Mondher Toumi (Autor)
• Format: Knjiga
• Izdano: Taylor & Francis Group, 2020-01-01T00:00:00Z.
• Teme: article
• Online pristup: Connect to this object online.

Background Morbidity and mortality associated with non-valvular atrial fibrillation (NVAF) imposes a substantial economic burden on the UK healthcare system. Objectives An existing Markov model was adapted to assess the real-world cost-effectiveness of rivaroxaban and apixaban, each compared with a...